In Vitro Cancer Diagnostics Global Market Report 2025

The in vitro cancer diagnostics market size has grown strongly in recent years. It will grow from $10.68 billion in 2024 to $11.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth observed during the historical period can be attributed to the rising prevalence of cancer, heightened awareness among patients regarding early cancer detection, increased adoption of molecular diagnostic techniques, expanded investments in healthcare infrastructure, and a growing focus on research in biomarker discovery for cancer diagnostics.

The in vitro cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $15.54 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth during the forecast period is driven by the increasing demand for personalized medicine in oncology, rising demand for point-of-care cancer diagnostics, growing awareness of minimally invasive testing methods, increasing investment in biotech and diagnostic startups, and rising need for cost-effective diagnostic solutions. Primary trends in the forecast period include advancements in liquid biopsy technology, integration with artificial intelligence, innovation in microfluidics platforms, development of digital pathology systems, and progress in genomic data analysis.

The rising adoption of liquid biopsy technologies is expected to enhance the growth of the in vitro cancer diagnostics market in the coming years. Liquid biopsy technologies refer to minimally invasive diagnostic methods that detect and analyze biomarkers such as circulating tumor DNA, circulating tumor cells, or exosomes present in body fluids like blood, urine, or saliva to monitor disease presence, progression, or response to treatment, particularly in cancer. The use of liquid biopsy technologies is increasing due to advancements in isolating and analyzing circulating tumor DNA and circulating tumor cells from blood and other body fluids. In vitro cancer diagnostic solutions are experiencing higher demand as the rapid adoption of liquid biopsy technologies encourages companies to implement non invasive and real time molecular profiling tools for cancer detection and treatment guidance. For example, in May 2025, according to NHS England, a UK based public healthcare system, the new liquid biopsy blood test rollout in the UK is expected to benefit up to 15,000 patients with suspected lung cancer and 5,000 women with advanced breast cancer annually, expanding from about 2,200 patients tested during the early 2025 rollout to an estimated 20,000 patients per year by 2028. Therefore, the rising adoption of liquid biopsy technologies is enhancing the growth of the in vitro cancer diagnostics market.

Leading companies operating in the in vitro cancer diagnostics market are emphasizing the development of AI-driven cancer diagnostics to improve patient outcomes and advance personalized healthcare. AI-driven cancer diagnostics involve the use of artificial intelligence to analyze medical and molecular data from patient samples, imaging, or genetic tests, enabling highly accurate detection, diagnosis, and prediction of cancer. For instance, in September 2024, Roche, a Switzerland-based pharmaceutical company, introduced the Digital Pathology Open Environment, a collaborative platform that securely integrates advanced AI-based image analysis tools from Roche and multiple third-party developers. The platform allows pathologists to access innovative algorithms within Roche’s Navify Digital Pathology enterprise software, enhancing diagnostic precision and workflow efficiency. By fostering collaboration and data sharing, the platform accelerates innovation in cancer diagnostics and research, supports precision medicine, and enables more effective targeted treatments, expanding global access to advanced digital pathology solutions.

In February 2024, Veracyte Inc., a US-based molecular diagnostics company, acquired C2i Genomics, Inc. for an undisclosed amount. Through this acquisition, Veracyte aims to expand its presence across the cancer care continuum by incorporating AI-driven whole-genome minimal residual disease testing to enhance treatment monitoring and detect disease recurrence. C2i Genomics Inc. is a US-based biotechnology company that provides in vitro cancer diagnostics.

Major players operating in the in vitro cancer diagnostics market are F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, Illumina Inc, Hologic Inc, Qiagen N.V, Bio-Rad Laboratories Inc, Agilent Technologies, Becton, Dickinson and Company (BD), Sysmex Corporation, LabCorp Holding Corp., Guardant Health, Quest Diagnostics, Exact Sciences, Myriad Genetics Inc, Natera Inc., NeoGenomics Laboratories, NanoString Technologies Inc, Caris Life Sciences, Transasia Bio-Medicals Ltd, Autobio Diagnostics Co Ltd, QuidelOrtho Corporation, Cancer Diagnostics Inc, Predicine Inc, Strata Oncology, Biocept Inc, Lucence Diagnostics.

North America was the largest region in the in vitro cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The in vitro cancer diagnostics market research report is one of a series of new reports that provides in vitro cancer diagnostics market statistics, including in vitro cancer diagnostics industry global market size, regional shares, competitors with a in vitro cancer diagnostics market share, detailed in vitro cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro cancer diagnostics industry. This in vitro cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In vitro cancer diagnostics refers to laboratory-based tests conducted on samples such as blood, tissue, or other body fluids to detect, monitor, or evaluate cancer outside the human body. These diagnostics employ techniques like molecular assays, biomarker analysis, and genetic profiling to identify the presence or progression of cancer. They support early detection, accurate diagnosis, and informed treatment planning for patients.

The key product types in in vitro cancer diagnostics include kits, instruments, reagents, software, and consumables. Kits are ready-to-use sets of reagents and materials designed for diagnostic testing, enabling biomarker detection, supporting disease monitoring, and assisting in treatment evaluation. Technologies used include polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry, and others. These diagnostics are applied across multiple cancer types, including breast cancer, lung cancer, colorectal cancer, and prostate cancer, and serve end users such as hospitals, diagnostic laboratories, research institutes, home care settings, and others.

The countries covered in the in vitro cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The in vitro cancer diagnostics market consists of revenues earned by entities by providing services such as molecular diagnostic testing, biopsy and cytology analysis, companion diagnostic services, and next-generation sequencing (NGS) services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro cancer diagnostics market also includes sales of cancer biomarker kits, molecular diagnostic assays, flow cytometry kits, tissue-based diagnostic kits, and genomic testing panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.